基底刚度在恶性肿瘤治疗中的作用

doi:10.3760/cma.j.cn371439-20201122-00108

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (9): 557-559.doi: 10.3760/cma.j.cn371439-20201122-00108

基底刚度在恶性肿瘤治疗中的作用

邓波儿, 孔为民()

首都医科大学附属北京妇产医院妇瘤科 100006

收稿日期:2020-11-22 修回日期:2020-12-28 出版日期:2021-09-08 发布日期:2021-09-22
通讯作者: 孔为民 E-mail:kwm1967@ccmu.edu.cn
基金资助:
北京市科技计划(Z161100000116030)

Role of substrate stiffness in the treatment of malignant tumor

Deng Bo'er, Kong Weimin()

Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China

Received:2020-11-22 Revised:2020-12-28 Online:2021-09-08 Published:2021-09-22
Contact: Kong Weimin E-mail:kwm1967@ccmu.edu.cn
Supported by:
Science and Technology Plan of Beijing Municipal of China(Z161100000116030)

摘要/Abstract

摘要：

基底刚度是细胞外基质重要的力学参数之一。不同的基底刚度均可影响肿瘤细胞的增殖、运动和细胞表型等细胞生物学行为。基底刚度变化与肿瘤细胞的放化疗敏感性相关,可引起肿瘤干细胞特性的改变和某些信号通路激活或失活,主要涉及ABCG2蛋白和Akt/mTOR/Sox2信号通路。进一步探讨基底刚度在恶性肿瘤放化疗以及靶向治疗中的作用,有望为恶性肿瘤的临床治疗提供依据。

关键词: 肿瘤, 化放疗, 分子靶向治疗, 基底刚度

Abstract:

Substrate stiffness is one of the important mechanical parameters of extracellular matrix. Different substrate stiffness will affect the proliferation, movement and phenotype of tumor cells. It is found that the change of substrate stiffness is also related to the chemotherapy and radiotherapy sensitivity of tumor cells. Substrate stiffness can cause changes in the characteristics of tumor stem cells, which are related to the activation or inactivation of some signaling pathways, mainly involving ABCG2 protein and Akt/mTOR/Sox2 signaling pathway. Further study on the role of substrate stiffness in radiotherapy, chemotherapy and targeted therapy of malignant tumor is expected to provide basis for the clinical treatment of malignant tumor.

Key words: Neoplasms, Chemoradiotherapy, Molecular targeted therapy, Substrate stiffness

邓波儿, 孔为民. 基底刚度在恶性肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2021, 48(9): 557-559.

Deng Bo'er, Kong Weimin. Role of substrate stiffness in the treatment of malignant tumor[J]. Journal of International Oncology, 2021, 48(9): 557-559.

参考文献 24

[1]	Darnell M, Gu L, Mooney D. RNA-seq reveals diverse effects of substrate stiffness on mesenchymal stem cells[J]. Biomaterials, 2018, 181:182-188. DOI: 10.1016/j.biomaterials.2018.07.039. doi: S0142-9612(18)30524-6 pmid: 30086447
[2]	Fiejdasz S, Horak W, Lewandowska-Łańcucka J, et al. Tuning of elasticity and surface properties of hydrogel cell culture substrates by simple chemical approach[J]. J Colloid Interface Sci, 2018, 524:102-113. DOI: 10.1016/j.jcis.2018.04.004. doi: 10.1016/j.jcis.2018.04.004
[3]	Jiang T, Zhao J, Yu S, et al. Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels[J]. Biomaterials, 2019, 188:130-143. DOI: 10.1016/j.biomaterials.2018.10.015. doi: 10.1016/j.biomaterials.2018.10.015
[4]	Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis[J]. Clin Exp Metastasis, 2019, 36(3):171-198. DOI: 10.1007/s10585-019-09966-1. doi: 10.1007/s10585-019-09966-1
[5]	Munoz A, Eldridge WJ, Jakobsen NM, et al. Corrigendum: cellular shear stiffness reflects progression of arsenic-induced transformation during G₁[J]. Carcinogenesis, 2019, 40(10):1298. DOI: 10.1093/carcin/bgz048. doi: 10.1093/carcin/bgz048
[6]	Shukla VC, Higuita-Castro N, Nana-Sinkam P, et al. Substrate stiffness modulates lung cancer cell migration but not epithelial to mesenchymal transition[J]. J Biomed Mater Res A, 2016, 104(5):1182-1193. DOI: 10.1002/jbm.a.35655. doi: 10.1002/jbm.a.35655 pmid: 26779779
[7]	Qin X, Lv X, Li P, et al. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(3):165625. DOI: 10.1016/j.bbadis.2019.165625. doi: 10.1016/j.bbadis.2019.165625
[8]	焦思萌, 赵轩宇, 宋丹, 等. 基底刚度对人宫颈癌HeLa细胞增殖及顺铂药物敏感性影响的体外研究[J]. 癌症进展, 2019, 17(22):2642-2644, 2651. DOI: 10.11877/j.issn.1672-1535.2019.17.22.09. doi: 10.11877/j.issn.1672-1535.2019.17.22.09
[9]	Wang W, Lollis EM, Bordeleau F, et al. Matrix stiffness regulates vascular integrity through focal adhesion kinase activity[J]. FASEB J, 2019, 33(1):1199-1208. DOI: 10.1096/fj.201800841R. doi: 10.1096/fj.201800841R
[10]	Chae YC, Kim JH. Cancer stem cell metabolism: target for cancer therapy[J]. BMB Rep, 2018, 51(7):319-326. DOI: 10.5483/bmbrep.2018.51.7.112. doi: 10.5483/bmbrep.2018.51.7.112
[11]	Chen Z, Zhu P, Zhang Y, et al. Enhanced sensitivity of cancer stem cells to chemotherapy using functionalized mesoporous silica nanoparticles[J]. Mol Pharm, 2016, 13(8):2749-2759. DOI: 10.1021/acs.molpharmaceut.6b00352. doi: 10.1021/acs.molpharmaceut.6b00352
[12]	Wang Y, Jiang F, Jiao K, et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties[J]. Exp Cell Res, 2020, 386(2):111739. DOI: 10.1016/j.yexcr.2019.111739. doi: 10.1016/j.yexcr.2019.111739
[13]	Hu J, Li J, Yue X, et al. Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2017, 37(2):231-236. DOI: 10.1007/s11596-017-1720-1. doi: 10.1007/s11596-017-1720-1
[14]	Hui L, Zhang J, Ding X, et al. Matrix stiffness regulates the proli-feration, stemness and chemoresistance of laryngeal squamous cancer cells[J]. Int J Oncol, 2017, 50(4):1439-1447. DOI: 10.3892/ijo.2017.3877. doi: 10.3892/ijo.2017.3877
[15]	Amawi H, Sim HM, Tiwari AK, et al. ABC transporter-mediated multidrug-resistant cancer[J]. Adv Exp Med Biol, 2019, 1141:549-580. DOI: 10.1007/978-981-13-7647-4_12. doi: 10.1007/978-981-13-7647-4_12
[16]	Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer[J]. Nat Rev Cancer, 2018, 18(7):452-464. DOI: 10.1038/s41568-018-0005-8. doi: 10.1038/s41568-018-0005-8
[17]	Sicchieri RD, da Silveira WA, Mandarano LR, et al. ABCG2 is a potential marker of tumor-initiating cells in breast cancer[J]. Tumour Biol, 2015, 36(12):9233-9243. DOI: 10.1007/s13277-015-3647-0. doi: 10.1007/s13277-015-3647-0
[18]	You Y, Zheng Q, Dong Y, et al. Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells[J]. Oncotarget, 2016, 7(22):32221-32231. DOI: 10.18632/oncotarget.8515. doi: 10.18632/oncotarget.8515
[19]	De Ruysscher D, Niedermann G, Burnet NG, et al. Radiotherapy toxicity[J]. Nat Rev Dis Primers, 2019, 5(1):13. DOI: 10.1038/s41572-019-0064-5. doi: 10.1038/s41572-019-0064-5 pmid: 30792503
[20]	Cree A, O'Donovan A, O'Hanlon S. New horizons in radiotherapy for older people[J]. Age Ageing, 2019, 48(5):605-612. DOI: 10.1093/ageing/afz089. doi: 10.1093/ageing/afz089
[21]	Panzetta V, Verde G, Pugliese M, et al. Adhesion and migration response to radiation therapy of mammary epithelial and adenocarcinoma cells interacting with different stiffness substrates[J]. Cancers (Basel), 2020, 12(5):1170. DOI: 10.3390/cancers12051170. doi: 10.3390/cancers12051170
[22]	Lacombe J, Harris AF, Zenhausern R, et al. Plant-based scaffolds modify cellular response to drug and radiation exposure compared to standard cell culture models[J]. Front Bioeng Biotechnol, 2020, 8:932. DOI: 10.3389/fbioe.2020.00932. doi: 10.3389/fbioe.2020.00932
[23]	Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. doi: 10.1016/S0140-6736(16)32453-9
[24]	Gao J, Rong Y, Huang Y, et al. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resis-tance through YAP[J]. J Cell Physiol, 2019, 234(3):2639-2648. DOI: 10.1002/jcp.27078. doi: 10.1002/jcp.27078

基底刚度在恶性肿瘤治疗中的作用

Role of substrate stiffness in the treatment of malignant tumor

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.